Breast Cancer Survival Rates: A 15-Year Progress Update
The battle against advanced breast cancer has seen remarkable advancements, offering renewed hope to patients. Recent research reveals a 7-month increase in survival rates for those diagnosed in 2025 compared to 2011. This progress is particularly notable for HER2-positive cancer patients, who now have a 11-19 month improvement in survival, depending on their hormone receptor status. However, triple-negative breast cancer patients still face the lowest survival rates, with a modest improvement over time.
The study, conducted by Thibaut Sanglier, PhD, and Eric Winer, MD, analyzed U.S. data from 68,626 patients treated for metastatic breast cancer since 2011. The findings highlight a 7-month increase in overall survival, from 27.5 months to 34.3 months, between 2011-2013 and 2020-2022. This improvement is attributed to more effective early-stage therapies, novel treatments, and better staging in the advanced setting.
The time gap between early-stage and advanced breast cancer has also widened, from 45 months in 2011 to 57 months in 2025, indicating a longer window for early intervention. Dr. Winer emphasizes the importance of global access to these life-saving treatments, ensuring that patients worldwide can benefit from these advancements.
Despite the progress, the study underscores the ongoing challenge of triple-negative breast cancer, where the unmet need remains significant. The research team invites discussions on how to further improve survival rates and support patients in their fight against this disease.
